EX-10.20



 Exhibit 10.20 

 
 



 
  
 



 
 AMENDMENT NO. 1 TO LOAN AGREEMENT 

This Amendment No. 1 (the “Amendment”) dated as of February 11, 2013, is between Bank of America, N.A. (the
“Bank”) and Insys Therapeutics, Inc. (the “Borrower”). 
 RECITALS 

A.    The Bank and the Borrower entered into a certain Loan Agreement dated as of February 15, 2012 (together
with any previous amendments, the “Agreement”). The current commitment amount of Facility No. 1 is $15,000,000.00. 

B.    The Bank and the Borrower desire to amend the Agreement. 

AGREEMENT 
 1.    Definitions. Capitalized terms used but not defined in this Amendment shall have the meaning given to them in the Agreement. 

2.    Amendments. The Agreement is hereby amended as follows: 

2.1.    In Paragraph 1.2 Availability Period, the “Facility No. 1 Expiration Date” is
changed to “February 15, 2014”. 
 3.    Representations and Warranties. When the
Borrower signs this Amendment, the Borrower represents and warrants to the Bank that (a) there is no event which is, or with notice or lapse of time or both would be, a default under the Agreement except those events, if any, that have been
disclosed in writing to the Bank or waived in writing by the Bank (b) the representations and warranties in the Agreement are true as of the date of this Amendment as if made on the date of this Amendment, (c) this Amendment does not conflict with
any law, agreement, or obligation by which the Borrower is bound, and (d) if the Borrower is a business entity or a trust, this Amendment is within the Borrower’s powers, has been duly authorized, and does not conflict with any of the
Borrower’s organizational papers. 
 4.    Conditions. This Amendment will be effective when the
Bank receives the following items, in form and content acceptable to the Bank. 
 4.1.    If
the Borrower or any guarantor is anything other than a natural person, evidence that the execution, delivery, and performance by the Borrower and/or such guarantor of this Amendment and any instrument or agreement required under this Amendment have
been duly authorized. 
 5.    Effect of Amendment. Except as provided in this Amendment, all of the
terms and conditions of the Agreement, including but not limited to the Waiver of Jury Trial, shall remain in full force and effect. 
 6.    Counterparts. This Amendment may be executed in counterparts, each of which when so executed shall be deemed an original, but all such counterparts together shall
constitute but one and the same instrument. 
 7.    FINAL AGREEMENT. BY SIGNING THIS DOCUMENT
EACH PARTY REPRESENTS AND AGREES THAT: (A) THIS DOCUMENT REPRESENTS THE FINAL AGREEMENT BETWEEN PARTIES WITH RESPECT TO THE SUBJECT MATTER HEREOF, (B) THIS DOCUMENT SUPERSEDES ANY COMMITMENT


  
 1 








 
LETTER, TERM SHEET OR OTHER WRITTEN OUTLINE OF TERMS AND CONDITIONS RELATING TO THE SUBJECT MATTER HEREOF, UNLESS SUCH COMMITMENT LETTER, TERM SHEET OR OTHER WRITTEN OUTLINE OF TERMS AND
CONDITIONS EXPRESSLY PROVIDES TO THE CONTRARY, (C) THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES, AND (D) THIS DOCUMENT MAY NOT BE CONTRADICTED BY EVIDENCE OF ANY PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OR UNDERSTANDINGS
OF THE PARTIES. 
 This Amendment is executed as of the date stated at the beginning of this Amendment. 

 

			
	Bank of America, N.A.
		
	By	 	/s/ Alpha Meyers
		 	ALPHA MEYERS, OFFICER


  

			
	 BORROWER(S):
  

Insys Therapeutics, Inc.

		
	By	 	/s/ Michael L. Babich
		 	Michael L. Babich



  
 2